Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 994 entries
View as:

Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis

Phase: N/A Priority: Normal
NCT ID: NCT00818948 Org: User:
Start: 03/31/09 End: 08/31/14 Due: 08/31/15

Study of Transitioning From Alendronate to Denosumab

Phase: N/A Priority: Normal
NCT ID: NCT00377819 Org: User:
Start: 09/30/06 End: 07/31/08 Due: 07/31/09

Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00317499 Org: User:
Start: 04/30/00 End: 07/31/02 Due: 07/31/03

Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00095277 Org: User:
Start: 10/31/04 End: - Due: -

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT06401044 Org: User:
Start: 05/30/24 End: 08/10/27 Due: 08/10/28

A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00306215 Org: User:
Start: 03/31/06 End: 06/30/09 Due: 06/30/10

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01253707 Org: User:
Start: 12/08/10 End: 12/13/16 Due: 12/13/17

A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01235416 Org: User:
Start: 09/30/05 End: 02/28/10 Due: 02/28/11

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Phase: N/A Priority: Normal
NCT ID: NCT04139226 Org: User:
Start: 08/28/19 End: 02/27/20 Due: 02/27/21

Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

Phase: N/A Priority: Normal
NCT ID: NCT00425035 Org: User:
Start: 02/28/03 End: - Due: -

A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06312020 Org: User:
Start: 05/09/24 End: 02/09/27 Due: 02/09/28

Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT01164917 Org: User:
Start: 08/31/10 End: 03/31/13 Due: 03/31/14

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00089635 Org: User:
Start: 08/01/04 End: 08/01/08 Due: 08/01/09

Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura

Phase: N/A Priority: Normal
NCT ID: NCT00415532 Org: User:
Start: 12/01/06 End: 05/11/09 Due: 05/11/10

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Phase: N/A Priority: Normal
NCT ID: NCT01952574 Org: User:
Start: 08/06/13 End: 11/12/19 Due: 11/12/20

The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

Phase: N/A Priority: Normal
NCT ID: NCT00002433 Org: User:
Start: - End: - Due: -

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00101907 Org: User:
Start: 12/31/04 End: 04/30/08 Due: 04/30/09

Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients

Phase: N/A Priority: Normal
NCT ID: NCT01723514 Org: User:
Start: 11/14/12 End: 07/10/14 Due: 07/10/15

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Phase: N/A Priority: Normal
NCT ID: NCT00460317 Org: User:
Start: 07/31/07 End: 08/31/13 Due: 08/31/14

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Phase: N/A Priority: Normal
NCT ID: NCT01984424 Org: User:
Start: 12/10/13 End: 11/21/17 Due: 11/21/18

EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction

Phase: N/A Priority: Normal
NCT ID: NCT05284747 Org: User:
Start: 10/26/22 End: 05/29/27 Due: 05/29/28

A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT03703908 Org: User:
Start: 10/01/18 End: 06/24/20 Due: 06/24/21

A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France

Phase: N/A Priority: Normal
NCT ID: NCT03757013 Org: User:
Start: 09/25/18 End: 09/10/21 Due: 09/10/22

A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

Phase: N/A Priority: Normal
NCT ID: NCT00986895 Org: User:
Start: 09/30/06 End: 06/30/07 Due: 06/30/08

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Phase: N/A Priority: Normal
NCT ID: NCT05267470 Org: User:
Start: 03/29/22 End: 05/28/24 Due: 05/28/25